Evidence map›Paper›PMID 37326121›Full record

ArticleCancer medicine2023

Prognostic value of Lynch syndrome, BRAF

Koen Zwart, Frederieke H van der Baan, Romain Cohen, Thomas Aparicio, Christelle de la Fouchardiére, Thierry Lecomte, Cornelis J A Punt, David Sefrioui, Rik J Verheijden, Geraldine R Vink and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Koen ZwartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-0369-4509
Frederieke H van der BaanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Romain CohenDepartment of Medical Oncology, Équipe Instabilité des Microsatellites et Cancer, Équipe Labellisée par la Ligue Nationale Contre le Cancer et SIRIC CURAMUS, Centre de recherche Saint Antoine, Hôpital Saint-Antoine, AP-HP, and INSERM UMRS 938, Sorbonne Université, Paris, France.
Thomas AparicioGastroenterology Department, Saint Louis Hospital, AP-HP, University of Paris, Paris, France.
Christelle de la FouchardiéreMedical Oncology Department, Léon Bérard Center, Lyon, France.ORCID 0000-0003-2291-5693
Thierry LecomteDepartment of Hepato-Gastroenterology and Digestive Oncology, Tours University Hospital and INSERM UMR 1069 N2C, University of Tours, Tours, France.
Cornelis J A PuntDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
David SefriouiDigestive Oncology Unit, Department of Hepatogastroenterology, Rouen University Hospital, IRON Group and INSERM U1245, University of Normandy, Rouen, France.ORCID 0000-0002-0821-5642
Rik J VerheijdenDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Geraldine R VinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
G Emerens WensinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-4103-5811
Aziz ZaananDepartment of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance publique-Hôpitaux de Paris, SIRIC CARPEM, University Paris Cité, Paris, France.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
David TougeronHepato-Gastroenterology Department, Poitiers University Hospital, University of Poitiers, Poitiers, France.ORCID 0000-0002-8065-9635
Jeanine M L RoodhartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-1398-8970
Utrecht University · NLInserm · FRUniversité Paris Cité · FRCentre Léon Bérard · FRUniversité de Poitiers · FRUniversité de Tours · FRUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent knowledge on prognostic biomarkers (especially BRAF

methodsThis observational cohort study combined a population-based Dutch cohort (2014-2019) and a large French multicenter cohort (2007-2017). All mCRC patients with a histologically proven dMMR tumor were included.

resultsIn our real-world data cohort of 707 dMMR mCRC patients, 438 patients were treated with first-line palliative systemic chemotherapy. Mean age of first-line treated patients was 61.9 years, 49% were male, and 40% had Lynch syndrome. BRAF

conclusionBRAF

Indexed as

Colonic NeoplasmsColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisRectal NeoplasmsDNA Mismatch RepairFemaleHumansMaleMiddle AgedMulticenter Studies as TopicMutationObservational Studies as TopicPrognosisProto-Oncogene Proteins B-rafBRAF protein, humanProto-Oncogene Proteins B-rafdeficient mismatch repairLynch syndromemetastatic colorectal cancermicrosatellite instabilitymolecular biology

Identifiers

PMID37326121
PMCPMC10469760
OpenAlexW4380872014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.